Si Belle HydraNoor PN (2.5mL x 1ea)
Si Belle HydraNoor PN — Polynucleotide + Hyaluronic Acid
Si Belle HydraNoor PN combines 10 mg polynucleotide (PN) with 10 mg low-molecular-weight hyaluronic acid (HA) in a 2.5 mL presentation.
Product specifications
Product name: Si Belle HydraNoor PN
Polynucleotide (PN): 10 mg
Hyaluronic acid (HA): 10 mg; low molecular weight
Volume: 2.5 mL
Product composition
The formulation combines polynucleotide (PN) and low-molecular-weight hyaluronic acid (HA).
Polynucleotide is the DNA-derived polymer component. Hyaluronic acid is the second component in the PN + HA formulation.
Polynucleotide (PN): Amount: 10 mg; Description: DNA-derived polymer component
Hyaluronic acid (HA): Amount: 10 mg; Description: Low molecular weight
Presentation: Amount: 2.5 mL; Description: Si Belle HydraNoor PN
Understanding PN and PDRN
PN means polynucleotide. PDRN means polydeoxyribonucleotide. These names identify different types of DNA-derived preparations and should not be used interchangeably.
Full name: PN: Polynucleotide; PDRN: Polydeoxyribonucleotide
General source context: PN: DNA-derived polymers discussed in skin-quality research; PDRN: DNA-derived preparations discussed in tissue-repair research
Literature emphasis: PN: Hydration, tissue support and skin-quality endpoints; PDRN: Nucleotide metabolism and wound-related endpoints
Interpretation: PN: Composition, molecular size and purification depend on the preparation; PDRN: Class-level findings do not replace product-specific clinical data
PN + HA formulation concept
The supplied catalogue explains the PN component in relation to skin-quality and tissue-support research, and the HA-PN combination in relation to experimental skin models.
The product profile is 10 mg PN plus 10 mg low-molecular-weight HA in 2.5 mL.
What the two ingredients bring to the product concept
The catalogue presents PN as a key component of the formulation and describes it in relation to skin-quality and tissue-support endpoints. It pairs this component with low-molecular-weight HA. Its ingredient background explores hydration, tissue support and skin-quality measures for PN, and the roles of HA–PN combinations in experimental skin models.
Ingredient background included in the dossier
The dossier includes a 27-subject split-face comparison of PN and non-crosslinked HA in the periocular area. Some measured texture and pore outcomes favoured PN, while the abstract described in the dossier reports no significant difference between groups in VAS or GAIS improvement. A separate five-patient series describes changes in skin-quality measures after long-chain PN treatment.
The HA–PN experimental section describes a laboratory and mouse study in which selected conditions showed increased fibroblast migration and collagen-related measures. These sections concern other PN preparations and ingredient background; they are not described as a clinical trial of HydraNoor PN.
Quick product answers
What is the formula?: PN 10 mg and low-molecular-weight HA 10 mg, in a 2.5 mL presentation.
What does PN stand for?: Polynucleotide. The brochure separately defines PDRN as polydeoxyribonucleotide and distinguishes the two terms.
How is it presented?: The product dossier identifies Si Belle HydraNoor PN as a PN + HA formulation with its composition and volume displayed together on the opening product profile.
How does it relate to HydraNoor?: HydraNoor PN has the specified PN 10 mg + low-molecular-weight HA 10 mg profile. The separate HydraNoor catalogue describes an HA + PN product supplied as three 2.5 mL syringes per box.
View the full HydraNoor PN product guide
){kind=link}